Neutralizing Antibody Market

Neutralizing Antibody Market Propelled by Growing Demand for Antibodies to Treat Coronavirus


Neutralizing antibodies are monoclonal antibodies that can effectively bind to viruses to reduce their ability to infect host cells and neutralize their effects. Produced as immunotherapy for conditions like cancer and autoimmune diseases, neutralizing antibodies are in high demand to treat coronavirus. They bind to the spike proteins on the surface of SARS-CoV-2 virus and prevent viral entry into host cells.

The global Neutralizing Antibody Market is estimated to be valued at US$ 1.87 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The key trend propelling the growth of the neutralizing antibody market is the increasing demand for antibodies to treat coronavirus. With rising cases of COVID-19 across the globe, research on monoclonal antibodies is being prioritized to develop potential therapies against the disease. Several biotech companies and research institutes are working to identify, map and manufacture fully human neutralizing antibodies that can bind to the viral spike protein and treat infected patients. Major players like Regeneron, Eli Lilly and Vir Biotechnology have received emergency use authorization for their antibody therapies. The success of these initial treatments is likely to boost the demand for neutralizing antibodies in the coming years.

SWOT Analysis

Strength: The neutralizing antibody market has a large potential patient base for treatment of numerous diseases. These antibodies have ability to neutralize microbes or toxins effectively by binding to antigens.

Weakness: The development of neutralizing antibodies is highly costly and time consuming process. Insufficient research in certain therapeutic areas can be a challenge.

Opportunity: Growing research activities in developing novel neutralizing antibodies for infectious diseases, cancer and other unmet medical conditions present lucrative opportunities. Advances in antibody engineering methods will further support market growth.

Threats: Stringent regulatory processes for approval of neutralizing antibodies increases risk of failure and delays market entry. Emergence of alternative treatment options can threaten existing neutralizing antibody drugs.

Key Takeaways

The global neutralizing antibody market is expected to witness high growth over the forecast period. Advancements in monoclonal antibody technology and increasing research to develop antibodies for new disease indications are fueling the market expansion. . Global Neutralizing Antibody Market Size is estimated to be valued at US$ 1.87 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.

North America currently dominates the market and is projected to maintain its leading position during the forecast period. Presence of major players, rising healthcare investments, and growing adoption of biologic therapies support the regional market growth. The Asia Pacific market is anticipated to showcase fastest growth rate owing to rising healthcare spending, improving research infrastructure and increasing generic competition.

Key players operating in the neutralizing antibody market are Mohawk, Argenx, WuXi Biologics, Adagio Therapeutics, Vir Biotechnology, Abcam, Amgen, Roche, Regeneron Pharmaceuticals, AstraZeneca, Inotrem and Anthropic. These companies are implementing various strategies such as new product launches, collaborations and acquisitions to strengthen their market position.